The Role of Leptin Hormone, Neuropeptide Y, Ghrelin and Leptin/Ghrelin ratio in Obesogenesis
Medical and Pharmaceutical Journal · 2022
DOI: 10.55940/medphar20227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical and Pharmaceutical Journal, 2022. Verfasst von Hany A. Al-hussaniy und 1 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref).
Abstract (Originalsprache)
In addition to energy storage, the adipose tissue plays multiple important roles, particularly the secretion of biomolecules such as leptin that participate in the neuroendocrine regulation of appetite. Therefore, this review sought to understand the influence of leptin on the genesis of obesity. A systemic review of the literature was conducted using articles published in English between 2016 and 2022. Ten experimental studies that introduced new approaches for treating leptin-resistant individuals were selected. The results showed that a structured food plan with a negative energy balance combined with a regular physical activity routine remains the best way to combat obesity and leptin resistance problems. It is possible to conclude that leptin resistance contributes to maintaining obesity. However, to date, there remains a lack of evidence that demonstrates a direct relationship between the poor function of this peptide and the genesis of obesity.
Zitieren
APA
Al-hussaniy, H. A., & AL-Biati, H. A. (2022). The Role of Leptin Hormone, Neuropeptide Y, Ghrelin and Leptin/Ghrelin ratio in Obesogenesis. Medical and Pharmaceutical Journal. https://doi.org/10.55940/medphar20227
Vancouver
Al-hussaniy HA, AL-Biati HA. The Role of Leptin Hormone, Neuropeptide Y, Ghrelin and Leptin/Ghrelin ratio in Obesogenesis. Medical and Pharmaceutical Journal. 2022. doi:10.55940/medphar20227
BibTeX
@article{Alhussaniy2022,
author = {Al-hussaniy, Hany A. and AL-Biati, Haedar A},
title = {The Role of Leptin Hormone, Neuropeptide Y, Ghrelin and Leptin/Ghrelin ratio in Obesogenesis},
journal = {Medical and Pharmaceutical Journal},
year = {2022},
doi = {10.55940/medphar20227}
}
EUVIMED